Prevention and treatment of ornithine aspartate for hepatic injury in patients with biliary pancreatitis after ERCP

Abstract

Objective To investigate the clinical value of ornithine aspartate in prevention and treatment of hepatic injury in patients with biliary pancreatitis after endoscopic retrograde cholangiopancreatography(ERCP). Methods From July 2011 to June 2015, 56 patients with biliary pancreatitis and hepatic injury after ERCP were selected. According to the order of hospitalization, the patients were numbered and equally divided into control group and observation group, with 28 cases in each group. The control group was given routine treatment, including gastrointestinal decompression, prevention of infection and parenteral nutrition support treatment. On this basis, the observation group was treated with ornithine aspartate. The changes of aspartate aminotransferase (ALT), alanine aminotransferase (AST), total bilirubin (TBIL), γ-glutamyl transpeptidase (GGT) and other liver function indexes before and after treatment were compared between the two groups. The relief time of abdominal pain, time of blood amylase (AMS) returning to normal level and hospitalization time in the two groups were statistically analyzed. The changes of serum interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α) and other inflammatory cytokines in the two groups were determined. Results ①After one week of treatment, the levels of ALT, AST, TBIL and GGT in the two groups were lower than those before treatment, and the decreasing amplitude in the observation group was greater than that in the control group (P<0.05); ②After one week of treatment, the levels of inflammatory factors in the two groups were lower than those before treatment, and the decreasing amplitude in the observation group was greater than that in the control group (P<0.05); ③The relief time of abdominal pain, time of AMS returning to normal level and hospitalization time of the observation group were shorter than those of the control group (P<0.05). Conclusions Ornithine aspartate can reduce the hepatic injury in patients with biliary pancreatitis after ERCP, and reduce the levels of serum inflammatory cytokines and shorten the recovery time after operation. Key words: Biliary pancreatitis; Endoscopic retrograde cholangiopancreatography; Ornithine aspartate; Hepatic injury